Novartis U.S. Shares Fall After Multiple Sclerosis Trial Results
Novartis reported two late-stage studies of its multiple sclerosis pill showed a reduction in flare-ups below that achieved by a rival Roche drug.
Novartis’s U.S. shares declined after the Swiss drugmaker reported findings from two late-stage studies of its multiple sclerosis pill. The reduction in flare-ups was smaller than that achieved by a rival Roche Holding drug. Novartis American depositary receipts fell as much as 4.5…